857283-98-8

Usage

Uses

Used in Pharmaceutical Industry:
BENZO[B]FURAN-3-YLACETYL CHLORIDE is used as a versatile intermediate for the synthesis of various pharmaceuticals. Its reactive acetyl chloride group allows for the formation of a wide range of organic compounds, making it a valuable building block in the development of new drugs.
Used in Agrochemical Industry:
BENZO[B]FURAN-3-YLACETYL CHLORIDE is also used as a key intermediate in the production of agrochemicals. Its ability to form various organic compounds makes it useful in the synthesis of pesticides, herbicides, and other agricultural chemicals.
Used in Organic Synthesis:
BENZO[B]FURAN-3-YLACETYL CHLORIDE is used as a reactive intermediate in organic synthesis for the production of a variety of organic compounds. Its acetyl chloride functional group allows for the formation of esters, amides, and other organic compounds, making it a valuable tool in the synthesis of complex molecules.
It is important to handle BENZO[B]FURAN-3-YLACETYL CHLORIDE with care due to its corrosive and irritating nature. Proper safety measures should be taken to minimize exposure and potential hazards.

InChI:InChI=1/C10H7ClO2/c11-10(12)5-7-6-13-9-4-2-1-3-8(7)9/h1-4,6H,5H2

Upstream product

• 64175-51-5 2-(3-benzofuranyl)acetic acid 
• 82156-58-9 benzofuran-3-yl-acetic acid ethyl ester 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 

Downstream Products

• 1070313-28-8 N-(2-(benzofuran-3-yl)acetyl)-5-bromo-N-(2-methylbenzyl)furan-2-carboxamide 

Relevant academic research and scientific papers

FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Facile preparation of protected benzylic and heteroarylmethyl amines via room temperature Curtius rearrangement

A step-wise, room temperature procedure for acyl azide formation and the subsequent Curtius rearrangement of phenyl and heteroaryl acetic acids is described. We have developed a protocol for room temperature Curtius rearrangement in MeOH or CHCl3 that provides an improvement over standard conditions, avoiding the use of additives or heat. This room temperature optimization of the Curtius rearrangement prevents the formation of side products often observed with benzylic acids, allowing access to a variety of benzylic and heteroarylmethyl amines.

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H] quinoline-4-carboxylic acid (PSI-697): Identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

Intramolecular carbenoid insertions: Reactions of α-diazo ketones derived from furanyl-, thienyl-, (benzofuranyl)-, and (benzothienyl)acetic acids with rhodium(II) acetate

α-Diazo ketones tethered to furan, benzofuran, thiophene, and benzothiophene by a single methylene spacer have been shown to undergo atypical, rhodium(II) acetate catalyzed chemistry. For example, while treatment of 1-diazo-3-(3-furanyl)-2-propanone with Rh2(OAc)4 resulted in the expected 2-(4-oxo-2-cyclopentenylidene)acetaldehyde, isomeric 1-diazo-3- (2-furanyl)-2-propanone undergoes a vinylogous Wolff rearrangement and in the presence of water gives a mixture of 6a-methyl-2,3,3a,6a-tetrahydrofuro [2,3- b]furan-2-one and 2-(2-methyl-3-furyl)acetic acid. Rhodium acetate catalyzed decomposition of 1-diazo-3-(3-benzofuranyl)-2-propanone and 1-diazo-3-(2- benzofuranyl)-2-propanone are also shown to undergo vinylogous Wolff rearrangement despite the fact that this chemistry is not observed with homologous benzofuranyl systems. α-Diazo ketones derived from benzothienyl propionic acids undergo the expected cyclization with 1-diazo-4-(3- benzothienyl)-2-butanone and 1-diazo-4-(2-benzothienyl)-2-butanone giving rise to 1,2,3,4-tetrahydrodibenzo[b,d]thiophen-3-one and 1,2,3,4- tetrahydrodibenzo[b,d]thiophen-2-one, respectively. While decomposition of 1- diazo-3(3-benzothienyl)-2-propanone resulted in the formation of 2,3-dihydro- 1H-benzo[b]cyclopenta[d]thiophen-2-one, the isomeric 1-diazo-3-(2- benzothienyl)-2-propanone gave a dimer which resulted from a [3 + 2] cycloaddition followed by a [1,3]-alkyl shift. Overall, the results from this study of intramolecular carbenoid insertion into five-membered heteroaromatic systems show that the resultant chemistry is dependent on the nature of the heteroatom, position of substitution, and the length of the aliphatic tether.